Trials / Terminated
TerminatedNCT03367871
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | IV |
| DRUG | Paclitaxel | Administered intravenously (IV) on day 1 |
| DRUG | Cisplatin | Administered intravenously (IV) on day 1 |
| DRUG | Carboplatin | Administered intravenously (IV) on day 1 |
| DRUG | Bevacizumab | Administered intravenously (IV) on day 1 |
Timeline
- Start date
- 2018-09-06
- Primary completion
- 2023-01-30
- Completion
- 2023-01-30
- First posted
- 2017-12-11
- Last updated
- 2024-06-18
- Results posted
- 2024-06-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03367871. Inclusion in this directory is not an endorsement.